Minor day-stay gynaecological procedures such as hysteroscopy and dilatation/curettage are common ambulatory procedures. High-quality postoperative analgesia is important in these settings in relation to patient satisfaction and preventing adverse outcomes such as unplanned admission 1 . Although the physiology of nociception from uterine and cervical stimulation has not been well established, it is known that prostaglandins are important mediators at peripheral and central locations and drugs which inhibit prostaglandin formation contribute significantly to pain relief associated with noxious stimuli to the uterus [2] [3] [4] . Both paracetamol and non-steroidal antiinflammatory drugs (NSAIDs) are commonly used for postoperative analgesia, with documented benefits in certain settings [4] [5] [6] [7] [8] [9] [10] . These drugs reduce menstrual pain 3, 11, 12 and both intravenous (IV) paracetamol and selective cyclooxygenase-2 inhibitors are widely available. Currently, parecoxib (Dynastat ® , Pfizer Australia, West Ryde, NSW, Australia) is the only IV cyclooxygenase-2 inhibitor licensed in Australia. We previously demonstrated that during minor gynaecological surgery there is no clear benefit from the administration of parecoxib the Women's and Newborn Health Service Ethics Committee (1882/EW) and the study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12611000345987). Women were considered eligible for the study if they had been scheduled for uterine dilatation and curettage (with or without hysteroscopy), were of age 18 to 70 years, American Society of Anesthesiologists physical status classification I or II, and provided written informed consent. The exclusion criteria included renal dysfunction, hypertension, ischaemic heart disease, cerebrovascular disease, past or current peptic ulcer or gastro-oesophageal reflux disease, non-steroidal anti-inflammatory drug-or aspirin-induced asthma, known allergy or hypersensitivity to paracetamol, parecoxib or sulphonamides, hepatocellular insufficiency or a history of postoperative nausea and vomiting (PONV) indicating the requirement for prophylactic antiemetic drugs. Participants who were unsuitable for general anaesthesia with maintenance by an inhalational agent, who required suxamethonium or intraoperative intubation, or who were taking an analgesia drug preoperatively were also excluded.
Participants were recruited in the day surgery unit on the day of their procedure. They were randomised and allocated immediately before surgery into one of four groups, using a computer-generated random number program and sequentially numbered opaque sealed envelopes. The procedural anaesthetist prepared and administered study drugs, which were recorded only as a coded number, such that the patient, study investigators and all other staff involved in the care of the patient were blinded to the group allocation. Study drugs were administered post-induction, the four study arms being 2 g IV paracetamol (Group A), 40 mg IV parecoxib (Group P), 2 g IV paracetamol and 40 mg IV parecoxib (Group AP) and IV saline (Group C).
Anaesthesia and postoperative analgesia was standardised. General anaesthesia consisted of IV fentanyl 1 to 1.5 μg/kg, propofol, sevoflurane in air/ oxygen and further IV fentanyl 25 to 50 μg as clinically required. Postoperative analgesia consisted of IV fentanyl (30 μg increments) in the recovery room and tramadol 100 mg orally every two hours as required (maximum 600 mg in 24 hours). PONV was managed as per an institutional protocol.
Preoperative data collected included age, American Society of Anesthesiologists class, body mass index, preoperative Quality of Recovery score 13 and use of misoprostol. Intraoperative data collected were the duration of surgery, time of study drug administration and total intraoperative fentanyl dose. Numerical rating pain scores (0 to 10) at rest and with movement were collected on arousal and at one, two and 24 hours postoperatively. The presence of sedation and other side-effects (including gastrointestinal irritation, PONV, headache and pruritus) were recorded by direct questioning. Total intra-and postoperative analgesic requirements were noted. At 24 hours participants were reviewed by telephone for their recovery data, including the presence and severity of side-effects, Quality of Recovery score, PONV score and the Overall Benefit of Analgesia Score, which assesses pain intensity, opioid-related adverse effects and patient satisfaction 14 .
Statistical analysis
The primary endpoints were the efficacy of the analgesic regimen as determined by pain scores with movement (sitting erect from the supine position) at one hour postoperatively and the Overall Benefit of Analgesia Score at 24 hours postoperatively. Based on data from a previous study performed at this institution 1 a sample size of 50 per group was required to detect a two point reduction in pain score with 
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A total of 270 women were recruited and 240 randomised (60 participants per group). All participants received the allocated treatment and were followed up prior to discharge from hospital ( Figure 1 ). Sixteen participants were lost to followup at 24 hours postoperatively. There were three major protocol violations (one in each of group C, P and AP), these participants receiving non-study paracetamol in the early postoperative period, but all were included in the analysis. The baseline demographics and intraoperative data of the participants did not differ between groups (Table 1) .
There was no statistically significant difference in pain score with movement at one hour or Overall Benefit of Analgesia Score between the four groups (P=0.12 and P=0.82 respectively, Table 2), nor was there for pain scores at rest and with movement at 1 hour, 2 hours and 24 hours postoperatively. The area under the curve of pain scores with movement in the periods 0 to 1 hour and 0 to 2 hours postoperatively differed significantly between groups in favour of group A (P=0.01, Table 3 ). The area under the curves for 0 to 1 hour and 0 to 2 hours were significantly lower in group A than in group C (P=0.01 and P=0.005 respectively). There were no significant differences between groups P or AP and group C (Table 4, Figure 2) .
The number of participants who requested tramadol and the time to first dose of tramadol were significantly different between the four groups ( Table  3 ). The time until 25% of participants in the group had requested tramadol in groups A and group AP was longer (Table 3) . Group P was not significantly different to group C. No inter-group differences were found in the perioperative use of fentanyl or the cumulative dose of tramadol used.
The incidence of PONV at two hours post-surgery was higher in group P (14%) than group C (0%), group A (4%) and group AP (8%) (P=0.011). The incidence of gastrointestinal irritation and/ or heartburn was higher in group P than the other groups, but no significant differences were found for the incidence of sedation, pruritus, headache or quality of recovery (Table 5 ).
DISCUSSION
In this study, there was no significant difference between groups in the primary outcome measures of postoperative analgesia after minor gynaecological surgery. Possible differences in early postoperative pain, indicated by lower overall scores and reduced requirement for rescue analgesia noted in groups receiving active drug, appeared to be clinically unimportant.
The findings from this study are in contrast to a number of previous studies of these analgesics in which clinically relevant reductions in either postoperative pain or opioid requirements have been noted 1, 4, [6] [7] [8] [9] [10] . The majority of studies showing benefit from paracetamol, parecoxib or both were conducted in different patient populations. The results are however, consistent with a previous study in a similar patient population which found that parecoxib resulted in only a small and clinically unimportant decrease in dynamic pain scores postoperatively 1 . A possible explanation for the different findings is that analgesic benefits occur only after surgery involving more major tissue damage (for example orthopaedic or major abdominal surgery), which produces a greater inflammatory and neuroendocrine response and more severe postoperative pain than that after minor procedures such as hysteroscopy and uterine curettage. Differences in somatic wound pain, which is prominent after major surgery, and Table 5 Postoperative adverse effects and QoR score visceral pain, as relevant to this study, may also be a reason for different responses. However, the rationale for use of coxibs in this setting is that they have been previously proven to provide effective analgesia where visceral pain is the major feature, for example dysmenorrhoea 3, 11, 12 and acute renal colic 15 . Pain scores after major surgery are frequently high, whereas in this study pain scores on arousal and in the early postoperative period were low in all groups, the median scores falling within the range of scores classified as representing 'mild' pain (numerical rating score less than three). Consequently, the reduction in pain from the multimodal regimens used in our study, compared with opioid-only analgesia, was small and clinically unimportant.
Gastrointestinal irritation
An apparent, early effect on postoperative pain associated with the intraoperative administration of IV paracetamol was not evident among patients receiving both paracetamol and parecoxib. While the mechanism of action of paracetamol has not been fully elucidated, the two drugs are thought to have different mechanisms of action which are not antagonistic. Previous studies support the benefits of combining these drugs 4, 6, 10 suggesting that the results observed in this study may have been due to chance or undetermined confounders.
The combination of IV paracetamol and parecoxib resulted in a substantial reduction in the need for supplemental analgesia after initial pain management with fentanyl in the recovery room. Whether this effect is of clinical relevance is open to debate. Tramadol is a relatively inexpensive drug and the study was not powered to investigate a difference in drug-related side-effects. In our opinion, the small reduction in tramadol requirements appeared of little clinical significance.
An unexpected finding was that the incidence of gastrointestinal side-effects was higher in the group receiving parecoxib, although not among patients receiving the combination of parecoxib and paracetamol. This finding was also inconsistent with a previous study among a similar population 1 . In addition, large studies such as the Vioxx Gastrointestinal Outcomes Research (VIGOR) and Celecoxib long-term Arthritis Safety Study (ClASS) have demonstrated the low incidence of adverse gastrointestinal events with the use of coxibs such as parecoxib, in both high-risk and low-risk populations 16, 17 . Given that there are multiple factors contributing to potential gastrointestinal side-effects, it may be that the patient groups in this study were imbalanced for risk factors for these effects.
This study has some limitations. Firstly, it investigated a specific ambulatory surgical population and the findings are unlikely to be generalisable to other patient populations undergoing different types of surgery. We used a loading dose of IV paracetamol that was more likely to rapidly establish a therapeutic analgesic concentration and a standard approved dose of parecoxib, but it is possible that higher plasma concentrations are required to control uterine visceral pain 18, 19 .
CONClUSION
In conclusion, the intraoperative administration of IV paracetamol 2 g and IV parecoxib 40 mg, either alone or in combination, in conjunction with IV fentanyl during minor day-stay gynaecological surgery, did not result in a clinically important decrease in pain either in the immediate postoperative period or across the first 24 hours after surgery, which included the post-discharge period. The routine administration of these drugs to patients undergoing these procedures does not appear to be warranted.
